Efficacy and Mechanism Analysis of Linezolid combined with Cyclosporine Capsule and Levofloxacin in the treatment of Drug-resistant Pulmonary Tuberculosis
Abstract：Objective: To discuss the clinical efficacy of linezolid combined with serine capsule and levofloxacin in the treatment of drug-resistant pulmonary tuberculosis. Methods: 78 cases of drug-resistant pulmonary tuberculosis treated in our hospital in May 2014 -2016 May were studied. According to the difference of the medication scheme, the patients were divided into the observation group (39 cases) and the control group (39 cases). The patients in the control group were treated with serine and levofloxacin on the basis of the national standard pulmonary tuberculosis treatment. The observation group was treated with linezolid on the basis of the control group. The therapeutic effects, serum levels of TNF-alpha, PCT, TOS, TAS and PON1 of the two groups were compared. Results: The effective rates of the observation group and the control group were (87.18%, 66.67%, P<0.05) respectively. After treatment, the absorption time, cavity closure time, acid fast staining negative time and sputum culture negative time in the observation group were shorter than those in the control group (P<0.05). Compared with before treatment, the levels of serum TNF- alpha, PCT and TOS in the two groups were significantly decreased, while the levels of TAS and PON1 were increased, and the changes of the above indexes were higher in the observation group (P<0.05). Conclusion: The clinical effect of linezolid combined with cycine serine capsule and levofloxacin in the treatment of drug-resistant tuberculosis is significant. It can significantly improve the clinical symptoms and shorten the turning time of sputum tuberculosis bacilli. It is worthy of clinical application.
张萌涛, 许优, 马进宝. 利奈唑胺联合环丝氨酸胶囊和左氧氟沙星治疗耐药肺结核的疗效及机制分析[J]. 河北医学, 2018, 24(8): 1304-1307.
ZHANG Mengtao, XU You, MA Jinbao. Efficacy and Mechanism Analysis of Linezolid combined with Cyclosporine Capsule and Levofloxacin in the treatment of Drug-resistant Pulmonary Tuberculosis. HeBei Med, 2018, 24(8): 1304-1307.
[1] 梁冰,黎意芬,黄瑞霞,等.耐药结核病人的耐药状况分析[J].临床肺科杂志,2011,16(6):891~892. [2] 孔华丽,于莹莹,冯端浩.耐多药肺结核的临床治疗现状与发展[J].中国医药,2013,8(1):135~136. [3] 中华医学会结核病学分会.肺结核诊断和治疗指南[J].中华结核和呼吸杂志,2001,24(2):70~74. [4] 孙明,王蔚文.临床疾病诊断与疗效判断标准[M].北京:科学技术文献出版社,2010.456~459. [5] 曾蜀.左氧氟沙星治疗耐多药肺结核临床观察[J].中国医药导报,2011,8(23):65~66. [6] 余丽然,杨焕群,刘树周.环丝氨酸对结核分枝杆菌的耐药性及耐药机制探讨[J].海峡药学,2017,6(3):132~133. [7] 梁建琴,王金河,武丽红,等.利奈唑胺治疗耐多药肺结核的临床观察[J].中国临床医生,2014,42(10):44~47. [8] 赵英杰.肺结核患者血液中VEGF、TNF-α、IL-6的表达研究[J].中国卫生检验杂志,2013,23(17):3388~3393. [9] 左蕾,李超,夏宇.降钙素原及C-反应蛋白在肺结核治疗中的意义[J].新疆医学,2013,43(4):12~15. [10] Gupta A, Nagaraja MR, Kumari P, et al, Association of MDR-TB isolates with clinical characteristics of patients from Northern region of India[J]. Indian J Med Microbiol, 2014, 32(3):270~276. [11] Ceron JJ, Tecles F. Tvarijonaviciute, A. Serum paraoxonase 1 (PON1) measurement: an update[J]. BMC Vet Res, 2014, 10(74):326~328.
2018, Vol. 24 
冀公网安备13080202000677号